RBX-6610

N/A

Report date: 2024/11/11 10:59:25
NME

Base Information

Drug NameRBX-6610
Drug Alias NameRBX-6610
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionEukaryotic translation initiation factor 4E inhibitorsRNA modulators
TargetsEukaryotic translation initiation factor 4ERibonucleic Acid
Therapy Area/IndicationsNeoplasm MetastasisCarcinoma, Non-Small-Cell LungNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesHong Kong
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesRibometrix Inc
China Registration ClassN/A

Develop Information

Active CompaniesRibometrix IncThe University Of Hong Kong
Inactive CompaniesN/A
Active IndicationsNeoplasm MetastasisCarcinoma, Non-Small-Cell Lung
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A